阿司匹林用于心血管疾病一级预防:美国预防服务工作组推荐声明
美国预防服务工作组(USPSTF)更新2016年推荐,委托系统评价与微模拟模型研究,评估无CVD病史成人使用阿司匹林一级预防CVD事件(心肌梗死、卒中)、心血管死亡与全因死亡的获益及出血等危害,并评估对结直肠癌(CRC)发病与死亡的影响。USPSTF以中等确定性认为,40–59岁且10年CVD风险≥10%者使用阿司匹林净获益小;60岁及以上者启用阿司匹林无净获益。据此给出C级推荐(40–59岁高危者个体化决策)和D级推荐(60岁及以上不推荐启用)。该声明为急诊/ICU之外的一级预防门诊决策提供依据。
要点
- USPSTF 以中等确定性认为,40–59岁且10年CVD风险≥10%的成人使用阿司匹林一级预防CVD事件有小的净获益。
- USPSTF 以中等确定性认为,60岁及以上成人启用阿司匹林一级预防CVD事件无净获益。
- 40–59岁且10年CVD风险≥10%者是否启用低剂量阿司匹林应个体化决策(C级推荐);出血风险未增加且愿意每日服用者更可能获益。
- USPSTF 不推荐60岁及以上成人启用低剂量阿司匹林进行CVD一级预防(D级推荐)。
- 适用人群为40岁及以上、无CVD症状或体征且无已知CVD、出血风险未增加的成人。
适用人群与场景
- 40岁及以上、无CVD症状或体征且无已知CVD(包括无心肌梗死或卒中史)、出血风险未增加的成人(如无胃肠道溃疡史、近期出血、其他增加出血风险的疾病或药物使用)。
诊断标准与关键阈值
- 10年CVD风险评估用于40–59岁成人:10年CVD风险≥10%者使用阿司匹林一级预防CVD事件有小的净获益(中等确定性)。
- 年龄分层:40–59岁且10年CVD风险≥10%者为个体化决策人群(C级推荐);60岁及以上者为不推荐启用人群(D级推荐)。
处置流程与药物剂量
- 40–59岁且10年CVD风险≥10%者:是否启用低剂量阿司匹林进行CVD一级预防应个体化决策(C级推荐);出血风险未增加且愿意每日服用低剂量阿司匹林者更可能获益。
- 60岁及以上者:不推荐启用低剂量阿司匹林进行CVD一级预防(D级推荐)。
研究设计与关键结果
- USPSTF 委托系统评价评估阿司匹林对无CVD病史者CVD事件(心肌梗死和卒中)、心血管死亡和全因死亡的有效性,以及对一级预防人群CRC发病和死亡的影响和出血等危害。
- USPSTF 委托微模拟模型研究评估阿司匹林一级预防CVD和CRC的净获益与危害平衡,按年龄、性别和CVD风险水平分层。
- USPSTF 以中等确定性认为,40–59岁且10年CVD风险≥10%的成人使用阿司匹林一级预防CVD事件有小的净获益。
- USPSTF 以中等确定性认为,60岁及以上成人启用阿司匹林一级预防CVD事件无净获益。
证据类型、等级与局限
- 证据类型:美国预防服务工作组(USPSTF)推荐声明,基于委托的系统评价和微模拟模型研究。
- 证据确定性:中等确定性(40–59岁且10年CVD风险≥10%者净获益小;60岁及以上者无净获益)。
- 推荐等级:40–59岁且10年CVD风险≥10%者个体化决策为C级推荐;60岁及以上者不推荐启用为D级推荐。
- 局限:原文未报告局限性
对床旁实践的改变
- 对40–59岁且10年CVD风险≥10%、出血风险未增加的成人,是否启用低剂量阿司匹林一级预防应个体化决策(C级推荐),愿意每日服药者更可能获益。
- 对60岁及以上成人,不推荐启用低剂量阿司匹林进行CVD一级预防(D级推荐)。
- 适用人群为无CVD症状或体征且无已知CVD、出血风险未增加的成人;不适用于有心肌梗死或卒中史等已知CVD者。
指南或共识出处
- US Preventive Services Task Force Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease(JAMA)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Cardiovascular disease (CVD) is the leading cause of mortality in the US, accounting for more than 1 in 4 deaths. Each year, an estimated 605 000 people in the US have a first myocardial infarction and an estimated 610 000 experience a first stroke.
OBJECTIVE: To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the effectiveness of aspirin to reduce the risk of CVD events (myocardial infarction and stroke), cardiovascular mortality, and all-cause mortality in persons without a history of CVD. The systematic review also investigated the effect of aspirin use on colorectal cancer (CRC) incidence and mortality in primary CVD prevention populations, as well as the harms (particularly bleeding) associated with aspirin use. The USPSTF also commissioned a microsimulation modeling study to assess the net balance of benefits and harms from aspirin use for primary prevention of CVD and CRC, stratified by age, sex, and CVD risk level.
POPULATION: Adults 40 years or older without signs or symptoms of CVD or known CVD (including history of myocardial infarction or stroke) who are not at increased risk for bleeding (eg, no history of gastrointestinal ulcers, recent bleeding, other medical conditions, or use of medications that increase bleeding risk).
EVIDENCE ASSESSMENT: The USPSTF concludes with moderate certainty that aspirin use for the primary prevention of CVD events in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk has a small net benefit. The USPSTF concludes with moderate certainty that initiating aspirin use for the primary prevention of CVD events in adults 60 years or older has no net benefit.
RECOMMENDATION: The decision to initiate low-dose aspirin use for the primary prevention of CVD in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk should be an individual one. Evidence indicates that the net benefit of aspirin use in this group is small. Persons who are not at increased risk for bleeding and are willing to take low-dose aspirin daily are more likely to benefit. (C recommendation) The USPSTF recommends against initiating low-dose aspirin use for the primary prevention of CVD in adults 60 years or older. (D recommendation).
参考来源
- Davidson KW, Barry MJ, Mangione CM, et al. Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2022. PMID: 35471505. doi:10.1001/jama.2022.4983
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。